Martin Reck

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Metastatic Breast Cancer

Clinical Practice

Small Cell Lung Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

This page only lists publications with an associated author ORCID identifier.

Publications

Nikolaj Frost, Martin Reck
Non-Small Cell Lung Cancer Metastatic Without Oncogenic Alterations. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 44 (3) (2024)
Helena Alexandra Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip Font, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis G Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong Wan Kim, Melissa Lynne Johnson, Yi-Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D Patel, Egbert F Smit, Karen L Reckamp, Qian Dong, Pomy Shrestha, Pang-Dian Fan, Parul Patel, Andrea Sporchia, David W Sternberg, Dalila Sellami, Pasi A Janne
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Charles M Rudin, Stephen V Liu, Ross Andrew Soo, Shun Lu, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W Dumoulin, Achim Rittmeyer, Chao-Hua Chiu, Ozgur Ozyilkan, Melissa Lynne Johnson, Alejandro Navarro, Silvia Novello, Yuichi Ozawa, Sammi Hiu Tam, Namrata S Patil, Xiaohui Wen, Meilin Huang, Tien Hoang, Raymond Meng, Martin Reck
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Paige Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J Monk, Danny Nguyen, Do Youn Oh, Alicia F C Okines, David M O'Malley, Paula Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cedric Van Marcke, Evan Y Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas Eldridge Stinchcombe, Tanios S Bekaii-Saab
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Marina-Chiara Garassino, Shirish M Gadgeel, Giovanna Speranza, Enriqueta Felip Font, Emilio Esteban, Manuel Dómine, Maximilian J Hochmair, Steven Francis Powell, Helge G Bischoff, Nir Peled, Francesco Grossi, Ross R Jennens, Martin Reck, Rina Hui, Edward B Garon, Takayasu Kurata, Jhanelle E Gray, Paul Schwarzenberger, Erin Jensen, M Catherine Pietanza, Delvys Rodriguez Abreu
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jordi Remon, Lizza E L Hendriks, Martin Reck
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, David Vicente, David Planchard, Luis G Paz-Ares, Johan Filip Vansteenkiste, Marina-Chiara Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki Hyeong Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung Chul Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J Antonia
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (12) (2022)
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Pluzanski, Jacobus Burgers, Mauricio Mahave, Samreen Ahmed, Adam J Schoenfeld, Luis G Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth J O'Byrne, Ravi G Gupta, Judith Bushong, Li Li, Steven I Blum, Laura J Eccles, Suresh R Ramalingam
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Martin Reck, Jordi Remon, Matthew D Hellmann
First-Line Immunotherapy for Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (6) (2022)
Taofeek Kunle Owonikoko, Keunchil Park, Ramaswamy Govindan, Neal Ready, Martin Reck, Solange Peters, Shaker R Dakhil, Alejandro Navarro, Jerónimo Rafael Rodríguez-Cid, Michael Schenker, Jong-Seok Lee, Vanesa Gutierrez, Ivor Percent, Daniel Morgensztern, Carlos Henrique Barrios, Laurent Greillier, Sofia Baka, Miten Patel, Wen Hong Lin, Giovanni Selvaggi, Christine Baudelet, Jonathan Baden, Dimple Pandya, Parul Doshi, Hye Ryun Kim
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (12) (2021)
Martin Reck, Delvys Rodriguez Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Ticiana A Leal, Jonathan W Riess, Erin Jensen, Bin Zhao, M Catherine Pietanza, Julie R Brahmer
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (21) (2021)
Michael J Boyer, Mehmet A N Şendur, Delvys Rodriguez Abreu, Keunchil Park, Dae Ho Lee, Irfan Cicin, Perran Fulden Yumuk, Francisco J Orlandi, Ticiana A Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te-Chun Hsia, Gregory A Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, null null
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (21) (2021)
Stephen V Liu, Martin Reck, Aaron S Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeño, Raffaele Califano, Makoto Nishio, Francisco Orlandi, Jorge Alatorre-Alexander, Ticiana A Leal, Ying Cheng, Jong-Seok Lee, Sivuonthanh Lam, Mark McCleland, Yu Deng, See Phan, Leora Horn
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (6) (2021)